VX-993 IV / Vertex - LARVOL DELTA

Vertex Announces Results from Phase 2 Study of VX-993 for the Treatment of Acute Pain (Vertex Press Release) - P2 | N=367 | NCT06619847 | Sponsor: Vertex Pharmaceuticals Incorporated | "Treatment with VX-993 did not result in a statistically significant improvement on the primary endpoint of the time-weighted Sum of the Pain Intensity Difference from 0 to 48 hours (SPID48) compared to placebo. VX-993 was generally safe and well tolerated...Based on these results, Vertex will not progress VX-993 into pivotal development as monotherapy in acute pain."

Discontinued • P2 data • Pain

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults (clinicaltrials.gov) - P1 | N=88 | Completed | Sponsor: Vertex Pharmaceuticals Incorporated | Active, not recruiting ➔ Completed

Trial completion • Pain

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults (clinicaltrials.gov) - P1 | N=88 | Active, not recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Recruiting ➔ Active, not recruiting

Enrollment closed • Pain

A Phase 1 Dose Escalation Study of Intravenous VX-993 in Healthy Adults (clinicaltrials.gov) - P1 | N=110 | Recruiting | Sponsor: Vertex Pharmaceuticals Incorporated | Not yet recruiting ➔ Recruiting

Enrollment open • Pain